MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 01-31-2026
Autolus Therapeutics plc Total Shareholders Equity 2011-2026 | AUTL
Annual Total Shareholders Equity Autolus Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 427 M | 111 M | 299 M | 313 M | 210 M | 255 M | 233 M | 143 M | 30.7 M | 10.5 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 427 M | 10.5 M | 203 M |
Quarterly Total Shareholders Equity Autolus Therapeutics plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 265 M | 346 M | 371 M | 477 M | 528 M | 582 M | 181 M | 229 M | 267 M | - | 161 M | - | - | 313 M | - | - | 300 M | 210 M | 237 M | 259 M | 287 M | 255 M | 270 M | 298 M | 218 M | 233 M | 255 M | 267 M | 127 M | 138 M | 143 M | - | - | - | 30.7 M | - | - | - | 10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 582 M | 10.5 M | 259 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
203 M | $ 18.46 | -0.22 % | $ 2.72 B | USA |
 |
Amgen
AMGN
|
5.88 B | $ 344.63 | 0.8 % | $ 185 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
466 M | $ 70.06 | 1.05 % | $ 9.37 B | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Biogen
BIIB
|
16.7 B | $ 179.46 | -0.24 % | $ 26.1 B | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.7 | 3.85 % | $ 17 M | USA |
 |
Adagene
ADAG
|
50.5 M | $ 2.6 | -5.45 % | $ 146 M | China |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 9.78 | 0.93 % | $ 1.57 B | Britain |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.14 | -0.95 % | $ 7.55 B |  Australia |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 4.32 | 7.67 % | $ 9.4 B |  Israel |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
Compugen Ltd.
CGEN
|
54.9 M | $ 1.83 | -0.3 % | $ 164 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-30.6 M | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Celldex Therapeutics
CLDX
|
747 M | $ 24.98 | 1.54 % | $ 1.61 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 226.97 | 0.38 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Cellectis S.A.
CLLS
|
309 M | $ 3.86 | 1.72 % | $ 116 M | France |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 109.35 | -3.87 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
680 M | $ 42.1 | 5.59 % | $ 4.35 B | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
728 M | $ 24.77 | 1.93 % | $ 2.93 B | USA |
 |
Cardiff Oncology
CRDF
|
82.9 M | $ 1.7 | -3.14 % | $ 81 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-109 M | $ 13.96 | 2.01 % | $ 4.31 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-476 M | $ 6.58 | - | $ 1.36 B | USA |